Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival FGFRi are effective treatment strategies for patients with advanced solid tumors harboring ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials A comprehensive search of PubMed/MEDLINE and EMBASE was ...

Zhejiang Doer Biologics Co., Ltd. (Doer Bio), a clinical stage biopharmaceutical company, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 ...

This disorder stems primarily from gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3) gene, which exerts widespread effects on skeletal development, leading to disrupted ...

Tyra Biosciences, Inc.’s TYRA share price has dipped by 5.48%, which has investors questioning if this is right time to buy.

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...